Related Experiment Videos
Antipyrine elimination by patients under treatment with monoamine oxidase inhibitors
Abstract:
1 Antipyrine elimination kinetics have been determined in fifteen patients before and after 4 weeks treatment with monoamine oxidase inhibitors and in five patients after treatment only. 2 Antipyrine elimination was slightly but significantly slowed by 28 days treatment with phenelzine but the degree of slowing was uninfluenced by acetylator phenotype or dosage of phenelzine administered. 3 The findings suggest that at the dosage used phenelzine is a weak inhibitor of hepatic microsomal mixed function oxidase in man and it is concluded that this is likely to provide an important source of drug interaction in some patients.
Insights
Monoamine oxidase inhibitors like phenelzine slightly slow antipyrine elimination. This suggests phenelzine weakly inhibits liver enzymes, potentially causing drug interactions in patients.
Area of Science:
- Pharmacology
- Drug Metabolism
- Clinical Pharmacokinetics
Background:
- Monoamine oxidase inhibitors (MAOIs) are used to treat depression.
- Hepatic microsomal enzymes are crucial for drug metabolism.
- Antipyrine is a model drug used to assess liver enzyme activity.
Purpose of the Study:
- To investigate the effect of phenelzine, a MAOI, on antipyrine elimination kinetics.
- To determine if phenelzine inhibits hepatic microsomal mixed-function oxidase activity in humans.
Main Methods:
- Antipyrine elimination was measured in 15 patients before and after 4 weeks of phenelzine treatment.
- Five additional patients received phenelzine treatment only.
- Acetylator phenotype and phenelzine dosage were considered.
Main Results:
- A slight but significant slowing of antipyrine elimination was observed after 28 days of phenelzine treatment.
- The observed slowing was independent of the patient's acetylator phenotype.
- Phenelzine dosage did not influence the degree of antipyrine elimination slowing.
Conclusions:
- Phenelzine appears to be a weak inhibitor of hepatic microsomal mixed-function oxidase at the studied dosage.
- This weak inhibition may represent a significant source of drug interactions in some patients.
- Further research is warranted to fully elucidate the clinical implications of phenelzine-induced enzyme inhibition.